Tivdak (tisotumab vedotin) approved by European Commission for previously treated recurrent or metastatic cervical cancer – Genmab
Genmab announced that the European Commission (EC) has granted marketing authorization for Tivdak (tisotumab vedotin), an antibody-drug conjugate (ADC), as monotherapy treatment for adult patients with recurrent or… read more.
